August proved volatile for PMS funds, with several small and midcap strategies logging steep losses—Valcreate’s Lifesciences fund plunged 10.19%. Yet, a few portfolios like Wallfort’s Avenue Fund and Valcreate’s Digital Disruption strategy posted modest gains, highlighting sharp performance divergence.
